Merck & Co., Inc. (NYSE:MRK) Shares Sold by Matthew Goff Investment Advisor LLC

Matthew Goff Investment Advisor LLC lessened its stake in Merck & Co., Inc. (NYSE:MRKFree Report) by 1.5% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 117,117 shares of the company’s stock after selling 1,842 shares during the quarter. Merck & Co., Inc. accounts for about 3.1% of Matthew Goff Investment Advisor LLC’s investment portfolio, making the stock its 10th biggest holding. Matthew Goff Investment Advisor LLC’s holdings in Merck & Co., Inc. were worth $15,454,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Wellington Management Group LLP boosted its holdings in shares of Merck & Co., Inc. by 3.8% in the fourth quarter. Wellington Management Group LLP now owns 85,595,999 shares of the company’s stock valued at $9,331,676,000 after buying an additional 3,153,333 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in Merck & Co., Inc. by 14.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 36,682,866 shares of the company’s stock worth $3,966,029,000 after purchasing an additional 4,731,152 shares during the last quarter. Norges Bank acquired a new position in Merck & Co., Inc. during the fourth quarter worth $3,108,366,000. Royal Bank of Canada boosted its holdings in Merck & Co., Inc. by 12.8% during the fourth quarter. Royal Bank of Canada now owns 14,972,074 shares of the company’s stock worth $1,632,255,000 after purchasing an additional 1,696,151 shares during the last quarter. Finally, Fisher Asset Management LLC boosted its holdings in Merck & Co., Inc. by 1.7% during the fourth quarter. Fisher Asset Management LLC now owns 13,566,968 shares of the company’s stock worth $1,479,071,000 after purchasing an additional 228,578 shares during the last quarter. Institutional investors and hedge funds own 76.07% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on MRK. Cantor Fitzgerald restated an “overweight” rating and set a $155.00 target price on shares of Merck & Co., Inc. in a report on Tuesday. Wells Fargo & Company increased their target price on shares of Merck & Co., Inc. from $130.00 to $135.00 and gave the stock an “equal weight” rating in a report on Wednesday, March 27th. TheStreet cut shares of Merck & Co., Inc. from a “b+” rating to a “c+” rating in a report on Monday, March 4th. Argus upgraded shares of Merck & Co., Inc. to a “strong-buy” rating in a research note on Wednesday, June 5th. Finally, Berenberg Bank increased their price target on shares of Merck & Co., Inc. from $140.00 to $143.00 and gave the company a “buy” rating in a research note on Monday, April 8th. One research analyst has rated the stock with a sell rating, three have given a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $133.00.

Check Out Our Latest Analysis on MRK

Merck & Co., Inc. Stock Performance

Shares of MRK traded up $1.05 during trading hours on Friday, hitting $130.72. The company had a trading volume of 17,182,704 shares, compared to its average volume of 7,458,603. The firm has a market cap of $331.09 billion, a price-to-earnings ratio of 145.24, a PEG ratio of 2.50 and a beta of 0.39. The business has a fifty day moving average of $128.85 and a 200-day moving average of $123.37. Merck & Co., Inc. has a 12 month low of $99.14 and a 12 month high of $133.10. The company has a quick ratio of 0.99, a current ratio of 1.25 and a debt-to-equity ratio of 0.77.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last issued its quarterly earnings data on Thursday, April 25th. The company reported $2.07 earnings per share for the quarter, beating the consensus estimate of $1.94 by $0.13. The company had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.21 billion. Merck & Co., Inc. had a net margin of 3.76% and a return on equity of 14.05%. The company’s revenue was up 8.9% on a year-over-year basis. During the same period in the prior year, the firm earned $1.40 earnings per share. Equities analysts anticipate that Merck & Co., Inc. will post 8.64 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, July 8th. Stockholders of record on Monday, June 17th will be given a $0.77 dividend. This represents a $3.08 annualized dividend and a dividend yield of 2.36%. The ex-dividend date is Monday, June 17th. Merck & Co., Inc.’s payout ratio is presently 342.22%.

Merck & Co., Inc. Company Profile

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

Featured Stories

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.